Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Virus-like particles |
Clinical data | |
Routes of administration | Oral |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|